This clinical trial is focused on studying the long-term safety and effectiveness of a treatment called ARO-APOC3 in adults with a condition known as dyslipidemia. Dyslipidemia is a medical condition where there is an abnormal amount of lipids, such as cholesterol and triglycerides, in the blood. The treatment being tested, ARO-APOC3, is a solution for injection that contains a special type of molecule designed to target and reduce a protein called apolipoprotein C-III, which is involved in lipid metabolism.

The purpose of this study is to evaluate how safe and effective ARO-APOC3 is when used over a long period. Participants in the study will receive the treatment through subcutaneous injections, which means the solution is injected under the skin. The study will monitor participants for any side effects and measure changes in various blood lipid levels, including triglycerides, non-high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol, among others.

This study is an extension of a previous trial, meaning it continues to observe participants who have already completed an earlier phase of treatment. The trial aims to provide more information on how ARO-APOC3 affects lipid levels in the blood over time and to ensure that it remains safe for long-term use. Participants will be closely monitored throughout the study to gather comprehensive data on the treatment’s impact on their health.